Amoxicillin 500 mg capsule
Public data on amoxicillin from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.
NADAC per unit, monthly
AMOXICILLIN 500 MG CAPSULEShow as table
| Month | NADAC per unit ($) |
|---|---|
| 2013-11 | 0.07211 |
| 2014-02 | 0.07811 |
| 2014-05 | 0.07472 |
| 2014-08 | 0.07501 |
| 2014-11 | 0.06815 |
| 2015-02 | 0.06882 |
| 2015-05 | 0.06985 |
| 2015-08 | 0.06609 |
| 2015-11 | 0.06432 |
| 2016-02 | 0.06488 |
| 2016-05 | 0.06613 |
| 2016-08 | 0.07822 |
| 2016-11 | 0.07959 |
| 2017-02 | 0.07022 |
| 2017-05 | 0.06879 |
| 2017-08 | 0.06802 |
| 2017-11 | 0.06725 |
| 2018-02 | 0.06382 |
| 2018-05 | 0.05971 |
| 2018-08 | 0.06309 |
| 2018-11 | 0.06225 |
| 2019-02 | 0.06190 |
| 2019-05 | 0.05892 |
| 2019-08 | 0.06240 |
| 2019-11 | 0.06417 |
| 2020-02 | 0.06404 |
| 2020-05 | 0.06670 |
| 2020-08 | 0.06366 |
| 2020-11 | 0.06516 |
| 2021-02 | 0.06979 |
| 2021-05 | 0.07072 |
| 2021-08 | 0.07220 |
| 2021-11 | 0.06818 |
| 2022-02 | 0.06963 |
| 2022-05 | 0.07286 |
| 2022-08 | 0.07382 |
| 2022-11 | 0.07722 |
| 2023-02 | 0.07227 |
| 2023-05 | 0.07974 |
| 2023-08 | 0.09760 |
| 2023-11 | 0.10233 |
| 2024-02 | 0.10328 |
| 2024-05 | 0.08842 |
| 2024-08 | 0.08916 |
| 2024-11 | 0.08537 |
| 2025-02 | 0.08450 |
| 2025-05 | 0.09157 |
| 2025-08 | 0.09346 |
| 2025-11 | 0.08944 |
| 2026-02 | 0.08612 |
| 2026-05 | 0.08236 |
| 2026-08 | 0.07803 |
| 2026-11 | 0.07925 |
Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.
Recall records mentioning amoxicillin
openFDA enforcement records, by year reported.
| 2025 | 1 |
| 2024 | 3 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 3 |
| 2016 | 3 |
| 2015 | 1 |
| 2014 | 1 |
20 records since 2012. A record is one product or lot, not one recall event. Combination products that contain amoxicillin are included.
What these numbers mean
NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.
Most recent recall records
Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.
Articles that mention amoxicillin
11 GxRadar articles cite or discuss this drug.
The amoxicillin shortage of 2022 and 2023
FDA declared a shortage of liquid amoxicillin on Oct. 28, 2022, during a surge of respiratory illness in children. What FDA said caused it, what it did, how prescribing shifted and what pharmacies paid.
The generics that cost pharmacies more than they did in 2014
Most generics in GxRadar's 47-drug basket got cheaper. Seven cost pharmacies more than in January 2014, led by furosemide at 2.8 times its 2014 price. What federal cost and shortage data show, drug by drug.
Nitrofurantoin and the antibiotic price story
Pharmacies paid $1.77 for a nitrofurantoin capsule in January 2014 and 28 cents in October 2026. How six oral antibiotics' prices diverged, why competition explains much of it, and where shortages fit.
Pediatric drug shortages
Seventeen drugs on FDA's current shortage list carry the agency's Pediatric tag. Most are hospital injections, four have been listed since 2012, and research shows what shortages like these have cost children.
Why antibiotics keep running short
Seven anti-infectives were on FDA's current shortage list in October 2026, one of them since 2015, and 30 more had discontinuation notices. Low prices and few makers explain much of it, federal research shows.
China's role in drug ingredients and the chemicals behind them
What FDA testimony, FDA site data and USP supply mapping show about China's share of US drug ingredients, from finished pills down to key starting materials.